Search clinical trials for: Genetically Engineered Hematopoietic Stem/Progenitor Cells

Total 769 results

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia

United States
University of Nebraska
National Cancer Institute (NCI)

Completed

Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease | Secondary Myelofibrosis

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

Recurrent Adult Acute Myeloid Leukemia | Granulocytic Sarcoma

United States
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center

Terminated

GVAX vs. Placebo for MDS/AML After Allo HSCT

Acute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Not yet recruiting

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

Recurrent Severe Aplastic Anemia | Refractory Severe Aplastic Anemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia and other conditions

United States
General Oncology, Inc.
Myriad Genetics, Inc.

Recruiting

SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells

Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Stage IV | Breast Cancer Stage IV | BRCA1 Mutation | BRCA2 Mutation | Pancreatic Acinar Cell Carcinoma | Metastatic Pancreatic Cancer | Breast Cancer Metastatic | HER2-negative Breast Cancer | Metastatic Pancreatic Ductal Adenocarcinoma and other conditions

United States
Ivan S Moiseev

Completed

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

Immune System Diseases | Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Acute Lymphoid Leukemia

Russian Federation
University of Colorado, Denver

Terminated

Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma | Smoldering Plasma Cell Myeloma | Plasmacytosis

United States
Cancer Research UK

Unknown

Fludarabine Phosphate, Melphalan, and Alemtuzumab Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed Hodgkin Lymphoma

Lymphoma
Institute of Hematology & Blood Diseases Hospital

Completed

Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Acute,Leukemia, Lymphoid

China
Morten Hostrup, PhD

Not yet recruiting

U-LABA/ICS Effects on Exercise Performance, Formoterol

Exercise Performance

Denmark
St. Jude Children's Research Hospital

Completed

Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Brain and Central Nervous System Tumors

United States, Australia, Canada
Fred Hutchinson Cancer Center

Terminated

O6-Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cell in Treating Patients With Malignant Gliomas

Glioblastoma | Gliosarcoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies

Diffuse Large B-Cell Lymphoma | Burkitt Lymphoma | Mantle Cell Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma | CD20-Positive Neoplastic Cells Present | Refractory Mature B-Cell Non-Hodgkin Lymphoma

United States
French Innovative Leukemia Organisation

Terminated

Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma

Lymphoma

France
Masonic Cancer Center, University of Minnesota

Completed

Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders

Lysosomal Storage Disease | Peroxisomal Disorder

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Uma Borate

Suspended

Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Terminated

Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Myelodysplastic/Myeloproliferative Neoplasms

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Stage 4S Neuroblastoma | Ganglioneuroblastoma | Stage 2A Neuroblastoma | Stage 2B Neuroblastoma | Stage 3 Neuroblastoma | Stage 4 Neuroblastoma | Stage 1 Neuroblastoma | Stage 2 Neuroblastoma

United States, Canada, Australia, New Zealand
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer

Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Primary Peritoneal Carcinoma | Malignant Ovarian Mixed Epithelial Tumor | Ovarian Mucinous Cystadenocarcinoma | Undifferentiated Ovarian Carcinoma | Stage III Ovarian Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia

Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia

United States
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Extraocular Retinoblastoma

United States, Canada, Australia, Brazil, Argentina, Egypt
University of Nebraska
National Cancer Institute (NCI)

Withdrawn

Donor Stem Cell Transplant, Pentostatin, and Total-Body Irradiation in Treating Patients With Hematological Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Nonmalignant Neoplasm

United States
National Institute of Allergy and Infectious Diseases...
PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN); Blood...

Recruiting

Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (BEAT-MS)

Relapsing Multiple Sclerosis | Relapsing Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis

United States
University of Nebraska
National Cancer Institute (NCI); Genentech, Inc.

Completed

Rituximab & Combination Chemotherapy Followed by Transplantation in Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

GM-CSF and Rituximab After Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

Lymphoma

United States
Gesellschaft fur Padiatrische Onkologie und Hamatologie...

Unknown

Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma

Neuroblastoma

Germany, Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation

Hematopoietic and Lymphoid Cell Neoplasm | Hematologic and Lymphocytic Disorder | Allogeneic Stem Cell Transplant Recipient

United States
Fred Hutchinson Cancer Center
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers

HIV Infection | Hematopoietic and Lymphoid Cell Neoplasm | Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Non-Hodgkin Lymphoma | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Chronic Myelogenous Leukemia, BCR-ABL1... and other conditions

United States
M.D. Anderson Cancer Center

Terminated

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Breast Cancer | Ovarian Cancer

United States
National Cancer Institute (NCI)

Completed

Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia

Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia

United States, Canada
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Secondary Myelofibrosis

United States
Nationwide Children's Hospital

Withdrawn

Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.

Neuroblastoma

United States
Masonic Cancer Center, University of Minnesota

Completed

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Acute Myelogenous Leukemia

United States
University of Chicago
National Cancer Institute (NCI)

Active, not recruiting

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma

United States, Canada
Bristol-Myers Squibb

Completed

Study to Characterize the Effects of Cytochrome p450 1A2 Inhibition on Systemic Exposure to BMS-986165

Healthy

United States
KK Women's and Children's Hospital

Completed

Closed-loop Double-vasopressor Automated System to Treat Hypotension During Spinal Anaesthesia for Caesarean Section

Hypotension
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Allogeneic Hematopoietic Stem Cell Transplantation for High-Risk Hematologic Malignancies Using One Haploidentical Donor

Hematopoietic/Lymphoid Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

Lymphoma | Acute Myeloid Leukemia | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Chronic Phase Chronic Myelogenous Leukemia | Recurrent Small Lymphocytic Lymphoma | Chronic Myelogenous Leukemia | Refractory Chronic Lymphocytic Leukemia and other conditions

United States
Nantes University Hospital

Not yet recruiting

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (CY-MET-RIC)

Hematologic Malignancy | Graft Versus Host Disease
Adam Kittai

Recruiting

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Transformed B-Cell Non-Hodgkin Lymphoma | Refractory Transformed Non-Hodgkin Lymphoma | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | Recurrent Transformed... and other conditions

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

Richter Syndrome | Recurrent Transformed Chronic Lymphocytic Leukemia | Refractory Transformed Chronic Lymphocytic Leukemia

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaborators

Recruiting

Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes

Hematopoietic and Lymphoid Cell Neoplasm | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Myelodysplastic Syndrome With Excess Blasts | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Biphenotypic Leukemia

United States
Stanford University

Completed

Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG

Multiple Myeloma | Blood and Marrow Transplant (BMT) | Transplantation, Autologous | Transplantation, Homologous

United States
Rafic Farah, MD

Completed

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

Lymphoma | Leukemia | Myelofibrosis | MDS

United States
European Inter-group Cooperation on Childhood and...

Unknown

Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma

Lymphoma

France, United Kingdom, Germany, Italy, Belgium, Switzerland, Austria, Czech Republic, Ireland, Netherlands, Poland, Sweden

Search clinical trials for: Genetically Engineered Hematopoietic Stem/Progenitor Cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations